Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety.
CONCLUSION: SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.
PMID: 25512476 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Reggia R, Franceschini F, Tincani A, Cavazzana I Tags: J Rheumatol Source Type: research
More News: Abatacept | Arthritis | Laboratory Medicine | Orencia | Rheumatoid Arthritis | Rheumatology